Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

MT-601 demonstrates favorable safety and durable responses in relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL)

View Full Paper
Ask AI
Bookmark
Share

Authors

MKManali KamdarUniversity of Colorado Cancer CenterLMLuke MountjoyColorado Blood Cancer InstituteMMMaria‐Bernadette MadelCentre National de la Recherche Scientifique

Discussion

Loading...

Member takes

Implication

Phase 1 trial shows MT-601 improves safety and efficacy in relapsed non-Hodgkin lymphoma, suggesting a promising treatment option.

Key Points

  • To evaluate the safety and efficacy of MT-601 in patients with relapsed or refractory non-Hodgkin lymphoma.
  • Phase 1, multicenter, open-label study
  • 33 patients enrolled across 9 clinical sites
  • Dose escalation with MT-601 cell doses ranging from 100 to 400 million cells
  • Favorable safety profile observed with no dose-limiting toxicities
  • 66% objective response rate reported in evaluable patients
  • 50% complete response rate, with durable responses lasting between 3 to 24 months

Cite This Study

Kamdar et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db35https://doi.org/10.1182/blood-2025-5944
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D)2025 · 1 citations
  2. 2Safety and efficacy of CD19/CD22/CD20 multi-targeted CAR-T therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma2025 · 1 citations
  3. 3Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas2015 · 78 citations
  4. 4The anti-CD20 antibody-drug conjugates TRS005 in relapse/refractory CD20-positive B-cell non-Hodgkin lymphoma: A multicenter, open-label, single-arm, phase I study.2024 · 1 citations
  5. 5Abstract CT269: Point-of-care manufacturing and early clinical evaluation of a tri-specific (CD19/20/22) CAR T-cell therapy for relapsed or refractory (R/R) B-cell malignancies2026